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PDE inhibitorProduction of high titer of antibodies against nuclear components is a hallmark of systemic lupus erythematosus,
an autoimmune disease characterized by the progressive chronic inﬂammation of multiple joints and organs.
Organ damage and dysfunction such as renal failure are typical clinical features in lupus. Cell hypermetabolism
and hypertrophy can accelerate organ dysfunction. In this study we focus on a speciﬁc murine model of lupus,
the MRL/lpr strain, and investigated the role of cyclic guanosine monophosphate (cGMP) catabolism in organ
remodeling of main target tissues (kidney, spleen and liver) in comparison with age-matched control mice. In
MRL/lpr-prone mice, the cGMP-phosphodiesterase (PDE) activities were signiﬁcantly increased in the kidney
(3-fold, P b 0.001), spleen (2-fold, P b 0.001) and liver (1.6-fold, P b 0.05). These raised activity levels were
paralleled by both an increased activity of PDE1 in the kidney (associated with nephromegaly) and in the liver,
and PDE2 in the spleen of lupus-prone mice. The up-regulation of PDE1 and PDE2 activities were associated
with a decrease in intracellular cGMP levels. This underlines an alteration of cGMP-PDE signaling in the kidney,
spleen and liver targeting different PDEs according to organs. In good agreement with these ﬁndings, a single in-
travenous administration to MRL/lpr mice of nimodipine (PDE1 inhibitor) but not of EHNA (PDE2 inhibitor) was
able to signiﬁcantly lower peripheral hypercellularity (P = 0.0401), a characteristic feature of this strain of
lupus-pronemice. Collectively, our ﬁndings are important for generating personalized strategies to prevent certain
forms of the lupus disease aswell as for understanding the role of PDEs and cGMP in the pathophysiology of lupus.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease char-
acterized by the production of antibodies targeting various components
of nuclear compartment of which the nucleosome, spliceosome, and
also phospholipids are frequently recognized [1]. Renal failure,
thrombosis and neurologic disorders are characteristic clinical features
of the illness in its advanced stages. Mesangial cell proliferation appears
to play an important role in the pathogenesis of progressive glomerular
abnormalities, leading to glomerulosclerosis and kidney dysfunctionsde Strasbourg, Biophotonique
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xicology, Faculty of Veterinary
des Nanoobjets, CBMN— UMR[2]. Massive splenomegaly has also been reported in about 10% of
the patients [3,4]. Widespread enlargement of the lymph nodes is also
common, particularly among children, young adults, and blacks of all
ages.
MRL/lpr lupus-prone mice develop clinical symptoms with
organomegaly [5]. Thismouse strain,which is themost commonly stud-
ied mouse model of the disease, bears an autosomal recessive mutation
in the gene encoding Fas [6]. TheMRL+/+ background is responsible for
the development of autoimmune kidney disease, and the lymphoprolif-
eration (lpr)/Fasmutation converts a mild nephritis into a much severe
disease, with a 50%mortality rate at 24 weeks of age [7,8]. Although the
molecular defect in this gene is not believed to be a cause for human SLE,
this mouse model remains relevant because it recapitulates many
biological, immunological and clinical features of the human disease.
In particular, some studies indicated that in this strain, the volume of
the kidney and spleen increases due to lymphocyte inﬁltration into
inﬂammatory sites [9,10] as also shown in lupus patients [11,12]. Histol-
ogy studies of these target organs conﬁrmed the occurrence of both in-
creased numbers of immune cells leading to hyperplasia, and increased
size of cells [9,13]. Very little is known, however, concerning cell prolif-
eration and hypertrophy in MRL/lpr mouse organomegaly during
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accelerate organ dysfunction [14].
Downstream of cyclic nucleotide synthesis by adenylyl and guanylyl
cyclases, cyclic nucleotide phosphodiesterases (PDEs) plays a pivotal
role in cyclic adenosine monophosphate (cAMP) and cyclic guanosine
monophosphate (cGMP) signaling by regulating protein kinase A
(PKA) and protein kinase G (PKG)-dependent phosphorylations, cyclic
nucleotide gated (CNG) channels, hyperpolarization-activated cyclic
nucleotide-gated (HCN) channels and the exchange protein directly
activated by cAMP (EPAC, also known as cAMP-GEF) [15]. This super-
family of enzymes hydrolyzes cAMP and cGMP as a quick feedback
mechanism to return to basal levels. In mammals, 11 PDE families are
currently known (PDE1–PDE11); most of them consist of several
isozymes and numerous PDE isozyme-splice variants. All PDEs share a
structural feature of a catalytic core, and they differ in substrate afﬁnity
(cAMP and/or cGMP), kinetic properties, speciﬁc inhibitor sensitivity
and allosteric regulators [15,16]. By regulating cyclic nucleotide levels,
PDEs contribute to their compartmentalization and govern many
biological processes among them cell adhesion, proliferation andmigra-
tion. Calcium/calmodulin (Ca2+/CaM) activated-PDE1 has been report-
ed to play an important role in cell proliferation and is implicated in
rodent heart hypertrophy [17,18]. Notably, in early cardiac hypertrophy
induced by angiotensin II, increases in PDE1 and PDE5 activities associ-
ated with increased expressions and in PDE2 activity were reported
[18]. In the sameway, PDE1 activity and expression increase in cirrhotic
rat kidneys after bile duct ligation [19]. Furthermore, we reported earli-
er in bovine aortic endothelial cells increases of cGMP-hydrolyzing ac-
tivities related to PDE1, PDE2 and PDE5 when cobblestone (quiescent)
phenotype transforms in spindle (angiogenic) phenotype [20], and in-
creases of PDE2 activity and mRNA levels in human vein endothelial
cells is stimulated by vascular endothelial growth factor [21]. Chronic
renal failure is associated with diminished nitric oxide availably and
many of the biological actions of nitric oxide aremediated by cGMP [22].
These observations led us to hypothesize that cGMP-PDEs may play
a role in MRL/lpr mouse nephritis and organ remodeling. In this study,
we investigated cGMP-PDE mRNA and protein expression activity and
location in MRL/lpr mice during disease progression in comparison
with age-matched healthy control mice.Table 1
Primers sequence and amplicon length.
Primers name Sequence Amplicon length bp
PDE1A forward 5′ CAC TGG CTC ACT GAA CTG GA 3′
PDE1A reverse 5′ GAC GTG GTG ATT CTC AAG CA 3′ 156
PDE1B forward 5′ TCA AGA ACC TGG ACC TCT GG 3′ 158
PDE1B reverse 5′ GGC CTC CAG AAA ACT CAT CA 3′
PDE1C forward 5′ GGT TCA AGA GCA TCG TCC AT 3′ 172
PDE1C reverse 5′ TGA TCT CCA CTG GCC TCA TT 3′
PDE2A forward 5′ TCC AGA CTG GTG TGT GAG GA 3′ 179
PDE2A reverse 5′ CCC AGT AGG TCC ACT TGC AT 3′2. Materials and methods
2.1. Materials
For PDE activity assessment, cyclic guanosine monophosphate
(cGMP), Tris, ethylene glycol tetraacetic acid (EGTA) and erythro-9-
(2-hydroxy-3-nonyl) adenine (EHNA) were from Sigma (St.
Louis, MO). Nimodipine and 1,3 dimethyl-6-(2-propoxy-5-meth-
ane-sulphonylamidophenyl)-pyrazolo[3,4-d] pyrimidin-4-(5H)-
one (DMPPO) were generous gifts from Bayer (Berlin, Germany)
and Pascal Grondin (Glaxo, Les Ullis, France), respectively. [8-3H]
cGMP (30–50 Ci mmol−1) was purchased from New England Nuclear
(Boston, MA) and puriﬁed by thin layer chromatography on silica gel,
using isopropanol:NH4OH:H2O (70:15:15) as the solvent. Nimodipine,
EHNA and DMPPO were dissolved in 100% dimethyl sulfoxide
(DMSO). The ﬁnal concentration of DMSO did not exceed 1% for PDE
activity assessment. The rabbit polyclonal antibodies to PDE1A
(#PD1A-101AP), PDE1B (#PD1B-201AP), PDE1C (#PD1C-301AP) and
PDE2A (#PD2A-112AP) from FabGennix, Frisco, TX, were used for
Western immunoblotting and immunohistochemistry analyses. Anti-
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody was
from Chemicon (Molsheim, France). Second antibodies used as horse-
radish peroxidase-conjugates were from Promega (Lyon, France). ECL
kit was from GE Healthcare (Uppsala, Sweden). Total RNA was isolated
using RNeasy mini Kit (Qiagen, Hidden, Germany) and their expression
analyzed by Q-PCR using Biorad kits (iScrpit™ cDNA Synthesis and iQ™SYBRGreen Supermix) in aMyIQ™ thermocycler. Speciﬁc primerswere
obtained from Invitrogen (Table 1).2.2. Animal model and treatments
Female CBA/J and MRL/lpr mice both sharing the same H-2k MHC
haplotype were purchased from Harlan (Gannat, France). Normal
mice that display other MHC haplotypes or genetic background were
not selected and evaluated in these studies. Mice were maintained in
controlled temperature room (25 °C) with a 12 hour-light/dark cycle
and were provided with food and water ad libitum. This investigation
was carried out in accordance with the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health Publication no.
85-23, revised 1996). All animal experiments were performed with
the approval of the local Institutional Animal Care and Use Committee
(CREMEAS).
For measuring in vivo effect of PDE inhibitors on peripheral
hypercellularity that develops with time in MRL/lpr mice, 11–
13 week-old MRL/lpr mice received either the inhibitors, or a control
molecule known to efﬁciently reduce white blood cell counts, or saline
only as non-treated control (single injection; intravenous route;
100 μg molecule/mouse; 8–9 mice per study group). Cell counts were
measured ﬁve days after injection using a Malassez counting chamber.2.3. Preparation of kidney, spleen and liver extracts
CBA/J and MRL/lpr mice were sacriﬁced at 8, 15 and 18 weeks to
study PDE activity in relation with lupus progression. At 8 weeks of
age, all mice were alive and had no proteinuria (pre-diseased), while
at 15 and 18 weeks, 10% and 20% mortality was observed, respectively,
and most of mice display signiﬁcant proteinuria [23]. Kidneys, spleen
and liver were isolated, immediately frozen in liquid nitrogen and
stored at −80 °C. Frozen tissues were powdered in liquid nitrogen
using amortar/pestle set-up. The resulting tissue powderswere homog-
enizedwith a glass–glass potter for 3 × 30 s at 4 °C in the following lysis
buffer: 20 mM Tris, pH 7.5, 5 mM EGTA, 150 mM NaCl, 20 mM Na-β-
glycerophosphate, 1 μMH-89, 10mMNaF, 1mMNaVO3, 1% (v/v) Triton
X-100, 0.1% (v/v) Tween 20, 166 μM Pefabloc, 133 μM aprotinin, 8.3 μM
bestatin, 2.5 μM E64, 3.3 μM leupeptin, and 1.6 μM pepstatin-A. The
homogenates were centrifuged at 14,000 g for 4 min at 4 °C and the
supernatants were stored as aliquots at −80 °C until used. Protein
concentrationwasquantiﬁed by the Lowry'smethod using a compatible
detergent assay.2.4. PDE activity measurements in tissue extracts
PDE activity was determined with a radio-enzymatic assay as
described previously [24]. Total cGMP-PDE activity was assessed at
1 μM cGMP and the contributions of PDE isozymes were determined
using selective inhibitors: 10 μM nimodipine for PDE1, 20 μM EHNA
for PDE2, 10 μM cilostamide for PDE3 and 0.1 μM DMPPO for PDE5.
Speciﬁc activities were expressed as pmol/min/mg of protein.
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PDE1, PDE3, PDE4 and PDE5 were isolated by anion-exchange
chromatography from bovine aortic smooth muscle cytosolic fraction
as previously described [25]. PDE2 was isolated from human platelets
[26]. Puriﬁed PDEs were stored as small aliquots at−80 °C until use.
The effects of drugs were studied on calmodulin (Ca2+/CaM) activated
PDE1, cGMP-activated PDE2, PDE3, PDE4 and PDE5. PDE activity was
determined at 1 μM substrate concentration by a radioenzymatic
assay as described previously [24]. The concentration of compounds
that produced 50% inhibition of substrate hydrolysis (IC50)was calculat-
ed by non-linear regression analysis (GraphPad Prism, SanDiego, CA) of
concentration–response curves performed at different drug concentra-
tions in the range of 1–100 μM. TheKi value for nimodipinewas estimat-
edwith 0.1 to 4 μMcGMP as the substrate for PDE1 andwith 0.2 to 4 μM
cAMP for PDE4.2.6. cGMP level measurements
Frozen tissueswere ground to aﬁnepowder under liquid nitrogen in
a mortar/pestle set-up. Tissues were weighted and homogenized in 10
volumes of 0.1 M HCl. Homogenates were centrifuged at 1000 g at
room temperature. The cGMP tissue levels were determined by Assay
Design™ Direct Cyclic GMP EIA Kit (Cayman Chemical Company, Ann
Arbor, MI).2.7. Analysis of PDE1, PDE2 protein expression pattern
Protein from kidney, spleen and liver extracts (30 μg) were subjected
to Western blot as described previously [27]. Brieﬂy, protein samples
were denatured and solubilized for 5 min at 95 °C in Laemmli buffer,
electrophoresed on SDS-8% polyacrylamide gel and electro-transferred
onto polyvinylidene ﬂuoride membranes. Immunodetection was carried
out with antibodies to PDE1A (1/2500), PDE1B (1/2500), PDE1C
(1/2500), and GAPDH (1/60,000). Antibody binding was detected by
chemiluminescence using horseradish peroxidase conjugates as
secondary antibodies (1/60,000), and an ECL kit. Autoradiography
signals were captured on a GeneGenius Bio Imaging System (Syngene,
Cambridge, UnitedKingdom)using theGeneSnap software and analyzed
using the GeneTools software. Statistical analysis was done with the
one-way analysis of variance and the Bonferroni's multiple comparison
tests.2.8. Renal PDE1 isoforms and spleen PDE2A mRNA expression by Q-PCR
Frozen tissues were ground in liquid nitrogen using the mortar/
pestle set-up. The resulting tissue-powders were homogenized with
glass–glass Potter 3 × 30 s at 1500 rpm in Qiazol lysis buffer. Total
RNA was extracted with Qiagen kit following manufacturer's instruc-
tions. RNA integrity and quality was veriﬁed in 4% (w/v)-agarose
gel, and its concentration assessed by spectrophotometry at 260 nm
(Genequant Pharmacia, Uppsala, Sweden). 1 μg of total RNA was
retro-transcripted in cDNA for ampliﬁcation in real time PCR using
MyIQ (Biorad). Speciﬁc primers were designed using consensus se-
quences of all variant given (http://www.ncbi.nlm.nih.gov/pubmed/)
of each subtype of PDE family (Table 1). Consensus sequences were ob-
tained with multiple alignments using the Mafft version 6 (http://align.
bmr.kyushu-u.ac.jp/mafft/online/server/). Speciﬁc primers of conserved
sequences of interestwere designedwith Primer3 Input (version 0.4.0).
These primers allowed us to amplify 1:20 of cDNA in real time PCR,
using iQ™ SYBR Green Supermix kit (Biorad) and MyIQ™ thermocycler
(Biorad). Amplicon lengths comprising between 150 and 200 base pairs
of DNA were checked by 4%-agarose gel electrophoresis.2.9. Immunohistochemistry staining of PDE1 isoforms in mouse kidneys
Kidneys were embedded in Tissue-Tek OCT compound and snap
frozen in methyl-butane with liquid nitrogen. Tissue sections (4 μm)
were ﬁxed with cold-acetone and incubated with anti-PDE1A, anti-
PDE1B and anti-PDE1C antibodies. After washing, bound antibodies
were revealed by Alexa-488 labeled secondary antibody (Molecular
Probes) followed by nucleus staining with DAPI. As a negative control,
primary antibodies were omitted. Pictures were obtained with an
epiﬂuorescence Nikonmicroscope using a CCD camera and NIS element
software (Nikon) at ×40 magniﬁcation.
2.10. Histology
Kidneys from 15week-oldmicewere harvested and ﬁxed for 48 h in
10% (v/v) buffered-formalin, pH 7.0 and embedded in parafﬁn. Sections
(2–4 μm thickness) were deparafﬁnized and stained with hematoxylin
and eosin. Pathological changes in the kidney were analyzed. The size
of glomeruli and tubules (3 glomeruli and 3 tubules for each kidney)
were measured with the Image J software.
2.11. Statistical analysis
Results are expressed as mean ± s.e.m. of n experiments and
statistically subjected to the one-way ANOVA variance analysis with a
Bonferroni post-test when necessary with P b 0.05 being considered
signiﬁcant. In the assaysmeasuring the effect ofmolecules onperipheral
cell counts, statistical signiﬁcance of data was assessed using the
Student's t-test.
3. Results
3.1. Characterization of cGMP-PDE activity in kidney, spleen and liver of
8 week-old CBA/J control mice
Fig. 1 shows that the kidney and spleen display comparable levels of
total cGMP-PDE activity and three times asmuch as liver. PDE1 was the
main cGMP hydrolyzing isozyme in the kidney (52%). PDE2 contribu-
tion was important in the spleen (40%) and was the main cGMP hydro-
lyzing isozyme in the liver (60%). PDE5 contribution was important in
the spleen (38%) and lower in kidney (10%) and liver tissues (14%).
These results demonstrate a certain degree of tropism regarding the
distribution of PDEs in healthy organs.
3.2. Tissue weight evolution in control and MRL/lpr mice
It is well established that MRL/lpr mice developmassive generalized
enlargement of lymph nodes. The mass of their spleen can also be
several times larger compared to controls. In the following, we thus
compared the weight of several organs collected from MRL/lpr mice
and haplotype-matched CBA/J mice used as control. We did not choose
to include MRL+/+ mice in this work because while MRL+/+ mice dis-
play the same MRL background as MRL/lpr mice, and are appropriate
controls for certain studies, they show much slower onset of lupus dis-
ease while being potentially abnormal compared to a normal setting.
Fig. 2 shows that compared to CBA/J mice, the mass of MRL/lpr kidneys
increased by 40% at 18 weeks with a signiﬁcant increase (+62%)
between 8 and 18 weeks of age; no signiﬁcant change was observed
in age-matched CBA/J mice (Fig. 2A). Similarly, compared to CBA/J
mice, the mass of the spleen of 18 week-old MRL/lpr signiﬁcantly
increased (+560%) with a signiﬁcant raise (+287%) between 8 and
18 weeks (Fig. 2B). The photographs shown in Fig. 3 allowed us to
visualize the huge increase of the MRL/lpr spleen and kidney sizes
while there was no apparent change of the liver size.
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old CBA/J control mice. Total cGMP-PDE activity and contribution of PDE1, PDE2, PDE3 and
PDE5 were assessed at 1 μM cGMP as described in the Material and methods. Data are
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and their evolution with disease progression
cGMP-PDE activities were assessed in the kidney (Fig. 4A), spleen
(Fig. 4B) and liver (Fig. 4C) of 8, 15 and 18 week-old CBA/J and MRL/lpr mice. Total cGMP-PDE activity in the kidney, spleen, and liver did
not signiﬁcantly vary with the age of CBA/J control mice. In contrast, it
signiﬁcantly increased in MRL/lpr mice. This increase was essentially
due to PDE1 in the kidney (Fig. 4A; 4.5-fold) and liver (Fig. 4C; 2-fold)
and to PDE2 in the spleen (Fig. 4B; 2 to 3-fold). PDE1 activities in the
kidney and liver were increased in pre-diseased mice of 8 weeks of
age and remained stably raised over disease progression. Splenic PDE2
activity, however, signiﬁcantly increased with disease progression be-
tween 15 and 18 weeks (that paralleled proteinuria progression in
these mice [23]). In contrast, signiﬁcant changes were detected neither
in the kidney and liver PDE2 activities, nor in the kidney, spleen and
liver PDE5 activities (not shown).
Those results demonstrate that: i) the distribution of PDEs in
MRL/lpr mice showed a certain degree of tropism as also found in
healthy organs; ii) PDE activities were raised in MRL/lpr mice
(PDE1 in the kidney and liver; PDE2 in the spleen); and iii) at least
for the spleen PDE2, there was an elevation of activity related to
the age of lupus mice. Further investigations were therefore
performed on 15 week-old mice in order to better understand the
dysfunctions of the PDE system in the pathophysiology of MRL/lpr
mice.3.4. Intracellular cGMP levels in the kidney, spleen and liver of control and
lupus mice
Fig. 5 shows that the intracellular cGMP level in CBA/J kidney
was about 30-fold higher compared to the liver and spleen. In
MRL/lpr tissues, this relative distribution remained globally similar.
However, compared to respective normal tissues, cGMP levels were
signiﬁcantly decreased, by 56% in the kidney and by 41% both in
the spleen and liver. This observation may be linked to the increase
of cGMP-PDE activities found in parallel in the same tissues (see
above).
MRL/lpr CBA/J 
Spleen
Kidney
Liver
Fig. 3. Internal view of the peritoneal cavity of 19 week-old MRL/lpr and CBA/J mice. The spleen of each mouse (MRL/lpr; CBA/J) is shown on the right.
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lupus mice
PDE protein expression pattern in the kidney revealed a major
80-kDa PDE1A band in both control and lupus-prone mice (Figs. 6A
and D). In addition a weak 62/58-kDa PDE1A signal was detected in
lupus-prone mice (Fig. 6A). The major signals for PDE1B (56 kDa) and
for PDE1C (68 kDa) were respectively down (−69%) and up (+46%)-
regulated in lupus kidney (Figs. 6A, F and H). In comparison with
controls, PDE1AmRNA expression remained unchanged in lupus kidney
(Fig. 6E), and both PDE1B (Fig. 6G) and PDE1C (Fig. 6I) mRNA expres-
sions were signiﬁcantly increased (respectively 2.7-fold and 3.4-fold;
Figs. 6G and I). In the spleen, a band migrating at 96 kDa and corre-
sponding to PDE2A was barely detectable in control mice while it was
signiﬁcantly increased (8-fold) in lupus mice (Figs. 6B and J). This in-
creased expression of PDE2A protein was correlated with a signiﬁcant
higher mRNA expression (5.6-fold; Fig. 6K). In the liver, PDE1A
(62 kDa), PDE1B (56 kDa) and PDE1C (68 kDa) were revealed by
Western blot (Fig. 6C). No change in their expression levels, both in
terms of protein (Fig. 6C) or mRNA (not shown), was observed when
normal and lupus mice were compared. Altogether, these results indi-
cate that in the kidney and spleen of MRL/lpr mice, the expression
level of several PDE isozymes was signiﬁcantly increased (68-kDa
PDE1C in the kidney and 96-kDa-PDE2A in the spleen) while in liver
no change could be observed. Increased expression of PDE proteins
was correlated at a transcriptional level by a raised expression of
corresponding mRNAs. PDE1B protein only was found to be clearly
down regulated in the kidney of lupus mice.3.6. Immunohistochemistry of PDE1 isozymes in the kidney of 15 week-old
CBA/J and MRL/lpr mice
PDE1A was clearly detected in CBA/J mice (Fig. 7A), whereas PDE1B
(Fig. 7C) and PDE1C (Fig. 7E) were weakly detected. An increase in
PDE1A, PDE1B and PDE1C immune signals was observed in lupus
mice. PDE1B was clearly detected in MRL/lpr mice by immunostaining
while it was barely detected byWestern blot in the total extract. A pos-
sible explanation would be that the recognition site of PDE1B proteinwould not be accessible to the anti-PDE1B antibody by Western blot.
Interestingly, the immunostaining data are in agreement with the
mRNA PDE1B data (Fig. 6G).3.7. Kidney histology of 15 week-old CBA/J and MRL/lpr mice
To further link the above-described data sets to some pathophysio-
logical features occurring in MRL/lpr mice, we examined tissue injury
in the kidneys of mice used in our studies. The size of glomeruli and
tubules was estimated by surface measurements. The kidney section
staining (Fig. 8A) with eosin–hematoxylin conﬁrmed that at this age,
and compared to age-matched normal mice, MRL/lpr mice were affect-
ed by an increased size of glomeruli (Figs. 8A and B) and tubules
(Figs. 8A and C). MRL/lpr kidneys exhibited an increased proliferation
of mesangial cells (Fig. 8A).3.8. Effects of PDE1 and PDE2 inhibitors on the peripheral hyperproliferation
measured in the blood of MRL/lpr mice
Since PDE1 and PDE2 activities and mRNA expression were
increased in MRL/lpr mice and found to be associated with a decrease
of cGMP level in their kidney and spleen, respectively, we wondered
whether PDE1 and/or PDE2-inhibitors might counterbalance, at least
in part and transiently, these abnormalities. The read-out used to evalu-
ate the potential effectiveness of PDE inhibitorswas themeasure of total
cell counts in the blood of treated mice. As negative and positive
controls, cell counts were measured in MRL/lpr mice that received sa-
line only (untreated arm) and inMRL/lprmice that received amolecule
known from earlier studies to efﬁciently restore the normal cell count
level (ctrl+), respectively. Fig. 9 shows that nimodipine, a selective
PDE1 inhibitor, (see supplemental data Table S1) and [28–30],
was able to signiﬁcantly decrease peripheral cell counts in treated
mice (P= 0.0401), whereas treatment of mice with EHNA, a selective
PDE2 inhibitor (see supplemental data Table S1) and [30,31], did not
signiﬁcantly affect cell counts (P = 0.0692). These results are in good
agreement with our data showing an increase of both PDE1 activity
and expression in the kidney of MRL/lpr mice.
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During disease progression, MRL/lpr lupus mice develop chronic
inﬂammation leading to multiple tissue damages affecting organ
remodeling. Previous studies have revealed that the lpr mutation,
which is a leaky mutation in Fas, induces a massive production of
lymphocytes in this mouse strain. Fas-null mice display substantialliver hyperplasia, lymphadenopathy and splenomegaly [32]. MRL/lpr
mice are known to progressively accumulate abnormal B and T
lymphocytes, notably CD3+CD4−CD8−B220+ double negative T cells,
and develop lymphadenopathy and splenomegaly.
In this study, we describe novel ﬁndings showing an increased PDE1
activity in the kidney and liver and an increased PDE2 activity in the
spleen of MRL/lpr mice. These observations in lupus can be added to
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Thus, PDE1A is implicated in kidney [19] and heart hypertrophy [17,
18] andPDE3 inmesangial cell proliferation-induced glomerulosclerosis
[2]. Similar to our present data in lupus kidney tissues, in the autosomal
dominant polycystic kidney disease, which is characterized by mural
epithelial cell proliferation, a high PDE1 contribution to total PDE
activity has been reported [33]. However, lower PDE1, PDE3 and PDE4
activities were found in polycystic murine kidneys compared to
wild-typemice. Altogether, these data show, in lupus as in other kidney
diseases, the existence of cGMP-PDE alterations that seem to target
certain key organs and tissues.
Considering the molecular mechanisms occurring behind these
variations of PDE distribution, we think that up-regulation of PDE1
activities in the kidney and liver and PDE2 activity in the spleen of
MRL/lpr mice could be related to cell proliferation and resistance to
cell apoptosis. Indeed, mutation in Fas (or TNFRSF6), a gene encoding
for a member of the TNF-receptor superfamily, is central in cellapoptosis. In lupus patients, and for reasons that are not related to any
alteration in the Fas gene, apoptotic cells and debris accumulate in
various tissues including germinal centers. In Fas-deﬁcient MRL/lpr
mice, an excellentmodel for studying the consequences of such a defect,
as in SLE patients, lymphocytes are resistant to TNFα-induced apoptosis
and may undergo proliferation in chronic inﬂammation context [34]. It
is widely thought that self-immunization is then driven by the defective
clearance of this excess of dying cells [35,36]. Previous studies in glo-
merular diseases have reported PDE3 up-regulation and implication of
this isozyme in renal mesangial cell proliferation; a PDE3 inhibitor
was found to reduce mesangial cell proliferation and nephromegaly
[2]. Our present study in murine lupus rather supports the implication
of PDE1 activity and expression in nephro- and splenomegaly. Over-
expression of PDE1 was signiﬁcantly associated with cGMP levels in
MRL/lpr kidney, spleen and liver that were clearly dropped compared
to control. In MRL/lpr mice, the cGMP pool is likely regulated by PDE1
in the kidney, as previously shown in rats [19], and by PDE2 in the
spleen. Apoptosis mediated by Fas–FasL pathway is positively correlat-
ed to intracellular cGMP increase and it was shown that apoptosis in-
creased in both human and rat pulmonary artery smooth muscle cells
in response to 8-bromo-cGMP stimulation [37]. These ﬁndings closely
support our data as we also found high cGMP-PDE activities and low
cGMP tissue levels associated with increased organs remodeling,
whichmight be due to lower apoptotic cell death. In rat heart hypertro-
phy induced by angiotensin II, concomitant cGMP level decrease and
PDE1 activity up-regulation were also reported [17]. This effect of
angiotensin II could be possibly extended to the glomerular damage in
MRL/lprmice, since it was clearly demonstrated that angiotensin inhibi-
tion reduces this damage in MRL/pr mice [9].
Reduced intracellular cGMP levels are suspected to initiate cell
hypermetabolism and protein accumulation [38]. Our present results
in lupus mice show that the increases in kidney PDE1 and spleen
PDE2 activities were correlated to the increases in PDE1C and PDE2A
protein and mRNA expression. Our results suggest that cGMP pool
controls and promotes cell proliferation, as it was previously reported
in human arterial smooth muscle cells for PDE1C [39].
Cellular localization of PDE1 isozymes was assessed by immunohis-
tochemistry in kidney section in focusing on glomeruli. Glomeruli con-
sist of one third of mesangial cells, and PDE1 overexpression in these
cells could explain mesangial proliferation induced glomerulomegaly
[40]. Furthermore, and consistently, kidney section stained with
eosin–hematoxylin revealed proliferation of mesangium in MRL/lpr
glomeruli and leukocyte recruitment, which participate in acute
renal failure [41]. Mesangial cells play an important role in kidney
function (ﬁltration) but their proliferation underlines epithelial-to-
mesenchymal transition leading to renal ﬁbrosis [42]. Our results sug-
gest that alteration of cGMP signaling in MRL/lpr kidney, spleen and
liver may lead to cell hyperplasia and to organ size increases as well as
other signal alterations, which might decrease survival rate. For in-
stance, hypoxia inducible factor (HIF), which is regulated (decreased)
by cGMP [43], leads to increased size of solid organs in patients with
Chuvash polycythemia [44].
In good agreement with our ﬁndings showing a decrease of cGMP
level inMRL/lpr kidney associated to PDE1 up-regulation, it was recent-
ly reported that MRL/lpr mice lacking nitric oxide synthase 3 (NOS3)
developed earlier a more severe disease with decreased survival [45].
Their renal cortices demonstrated increased superoxide production
(SO), whichwas blocked by both NOS andNADPHoxidase (NOX) inhib-
itors [45]. Angiotensin II, by activating NOX, increases reactive oxygen
species (ROS) production such as SO by activating NOX [46] and in-
creases Ca2+. Reciprocally, NO down-regulates NOX in renal mesangial
cells [47]. Altogether, these data focused on cGMPprompted us to inves-
tigate whether in vivo treatments of MRL/lpr mice with either PDE1 or
PDE2 inhibitors might ameliorate their disease. For this purpose, to in-
vestigate the effect of PDE1 and PDE2 inhibitors we used a sensitive
and rapid assay that was validated in previous studies [48–50]. It was
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mice against the disease upon administration of therapeutic peptides,
a test that lasts at least 8–9 months when usual tests are performed
(survival and proteinuria follow-up). Unfortunately potent and
selective inhibitor of PDE1 described in the literature such as ICOS com-
pounds [51,52] are not commercially available (for review see [30]).
Therefore we investigated the effect of nimodipine as a selective PDE1
inhibitor and EHNA as a selective PDE2 inhibitor. As shown in
Table S1, nimodipine inhibits selectively cGMP hydrolysis by PDE1with an IC50 value of 2.7 μM. i value of 0.6 i value of 21. Furthermore, it
does not inhibit either PDE2 or PDE5 activity. Moreover, nimodipine
competitively inhibits cGMP hydrolysis via calmodulin activated-PDE1
with a Ki value of 0.6 ± 0.02 μM, whereas it is 30-fold less potent on
cAMP hydrolysis via PDE4 with a Ki value of 21 ± 1 μM (Figs. S1).
EHNA signiﬁcantly inhibits PDE2 without acting on PDE1, PDE3, PDE4
or PDE5.
This is the ﬁrst study to date showing that nimodipine signiﬁcantly
reduces peripheral cell counts that are abnormally raised in MRL/lpr
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and PDE1C (E, F) speciﬁc antibodies (green color). Nuclei were stained with DAPI (blue
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nimodipine inhibits cell proliferation and PDE1A expression and in-
duces apoptosis in the lymphoblastic leukemia Jurkat cell model [53].
This remarkable result attesting the in vivo efﬁcacy of nimodipine
lupus disease gives further support to our ﬁndings showing the patho-
physiological importance of PDE1 in MRL/lpr mice. It also suggests
that nimodipinemight represent a pertinent drug to treat lupus patients
with proliferative lupus nephritis (PLN). Interestingly, it was recently
shown that total SO production was signiﬁcantly higher in SLE patients
with PLN [54]. One could hypothesize that the up-regulation of NOS
inducing SO production might be a feedback mechanism to overcome
kidney PDE1 up-regulation. Indeed, PDE1A expression and activity are
up-regulated by angiotensin II [18] and are associatedwith the develop-
ment of nitrate tolerance, in which NO-mediated vasodilation is
impaired [55]. Furthermore, PDE1 is known to be a regulator of
β-catenin and GSK3β, which are part of an important pathway for cell
growth [56,57]. Therefore, a targeted inhibition of up-regulated PDE1
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with NOS inhibitors. Nimodipine, which is currently used for the
treatment of patients suffering from hypertension, could then be
repositioned for overcoming lupus disease progression.5. Conclusion
Altogether, our ﬁndings lead us to propose potential therapeutic
strategies based on selective cGMP-PDE inhibitors, notably on PDE1
inhibitors, to thwart organomegaly and lupus disease progression.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.03.001.Competing interests
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